Patents by Inventor Michael T. Migawa
Michael T. Migawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250154506Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one chemical modification.Type: ApplicationFiled: February 11, 2022Publication date: May 15, 2025Applicant: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Michael Oestergaard, Mehran Nikan, Graeme C. Freestone, Michael T. Migawa, Brooke A. Anderson, Punit P. Seth, Eric E. Swayze
-
Patent number: 12234447Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: GrantFiled: March 17, 2022Date of Patent: February 25, 2025Assignee: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-Hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Publication number: 20240002851Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.Type: ApplicationFiled: January 25, 2023Publication date: January 4, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brooke A. Anderson, Xue-Hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
-
Publication number: 20230374519Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PMP22 RNA in a cell or animal, and in certain instances reducing the amount of PMP22 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include demyelination, progressive axonal damage and/or loss, weakness and wasting of foot and lower leg muscles, foot deformities, and weakness and atrophy in the hands. Such neurodegenerative diseases include Charcot-Marie-Tooth disease.Type: ApplicationFiled: June 18, 2021Publication date: November 23, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Eric E. Swayze, Holly Kordasiewicz, Punit P. Seth, Hien Thuy Zhao, Michael T. Migawa, Ruben E. Valas, Thazha P. Prakash
-
Publication number: 20230159922Abstract: The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside. An oligomeric compound comprising a modified oligonucleotide consisting of 12-30 linked nucleosides, wherein at least one nucleoside of the modified oligonucleotide is a stereo-non-standard nucleoside; and wherein the oligomeric compound is selected from among an RNAi compound, a modified CRISPR compound, and an artificial mRNA compound.Type: ApplicationFiled: August 14, 2020Publication date: May 25, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael T. Migawa, Graeme C. Freestone
-
Patent number: 11629348Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.Type: GrantFiled: February 15, 2022Date of Patent: April 18, 2023Assignee: Ionis Pharmaceuticals, Inc.Inventors: Brooke A. Anderson, Xue-hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
-
Publication number: 20230068063Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: ApplicationFiled: March 17, 2022Publication date: March 2, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Publication number: 20220186222Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.Type: ApplicationFiled: February 15, 2022Publication date: June 16, 2022Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brooke A. Anderson, Xue-hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
-
Patent number: 11332733Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: GrantFiled: February 12, 2019Date of Patent: May 17, 2022Assignee: lonis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Publication number: 20220064636Abstract: The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside.Type: ApplicationFiled: October 4, 2019Publication date: March 3, 2022Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael T. Migawa, Graeme C. Freestone
-
Publication number: 20210380976Abstract: The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having one or more chirally enriched phosphorothioate intemucleoside linkages. In certain embodiments, the modified oligonucleotide decreases expression of target mRNA.Type: ApplicationFiled: October 4, 2019Publication date: December 9, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Patent number: 11149264Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: GrantFiled: February 10, 2021Date of Patent: October 19, 2021Assignee: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Publication number: 20210261945Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: ApplicationFiled: February 10, 2021Publication date: August 26, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Publication number: 20210254059Abstract: The present invention provides gapped oligomeric compounds comprising from 1 to about 3 internucleoside linkages having one of formulas I to XVI. In certain embodiments, inclusion of from 1 to about 3 internucleoside linkages of one of formulas I to XVI, improves selectivity for a target RNA relative to an off target RNA. In certain embodiments, the improved selectivity also provides an improved toxicity profile. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount of activity or expression of the target nucleic acid in a cell.Type: ApplicationFiled: June 17, 2019Publication date: August 19, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael T. Migawa, Eric E. Swayze, Punit P. Seth
-
Publication number: 20210054017Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine anaologues.Type: ApplicationFiled: February 24, 2020Publication date: February 25, 2021Inventors: Punit P. Seth, Thazha P. Prakash, Michael T. Migawa, Eric E. Swayze
-
Publication number: 20210017513Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: ApplicationFiled: February 12, 2019Publication date: January 21, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Patent number: 10751419Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.Type: GrantFiled: September 7, 2018Date of Patent: August 25, 2020Assignee: Ionis Pharmaceuticals, Inc.Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Sayten P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
-
Patent number: 10570169Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine analogues.Type: GrantFiled: May 21, 2015Date of Patent: February 25, 2020Assignee: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Thazha P. Prakash, Michael T. Migawa, Eric E. Swayze
-
Patent number: 10450342Abstract: Provided herein are methods for removal of monomethoxytrityl groups from oligomeric compounds comprising terminally linked monomethoxytrityl protected amino groups. The present methods differ from standard methods for 5?-dimethoxytrityl removal from oligonucleotides in that the present methods are performed at elevated temperatures and higher pH. In certain embodiments, the present methods provide detritylated oligomeric compounds having a reduced percentage of depurination relative to the same detritylated oligomeric compounds prepared using standard methods. In certain embodiments, the present methods provide an increased rate of detritylation compared to standard methods. In certain embodiments, the modification of the final detritylation step results in an improved yield.Type: GrantFiled: February 23, 2016Date of Patent: October 22, 2019Assignee: Ionis Pharmaceuticals, Inc.Inventors: Dana Chreng, Michael T. Migawa
-
Publication number: 20190209694Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.Type: ApplicationFiled: September 7, 2018Publication date: July 11, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Sayten P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze